Advertisement

Topics

PeproStat Phase IIb Study Passes Recruitment Mid-Point Ahead Of Schedule

20:00 EDT 20 Jun 2017 | BioSpace

-Top line results brought forward to Q4 2017London, UK 21 June 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that its Phase IIb proof-of-concept study for PeproStat, Ergomeds highly innovative new coagulant, o...

Original Article: PeproStat Phase IIb Study Passes Recruitment Mid-Point Ahead Of Schedule

NEXT ARTICLE

More From BioPortfolio on "PeproStat Phase IIb Study Passes Recruitment Mid-Point Ahead Of Schedule"

Advertisement
Quick Search
Advertisement
Advertisement